Literature DB >> 22377518

Synthesis and evaluation of human phosphodiesterases (PDE) 5 inhibitor analogs as trypanosomal PDE inhibitors. Part 2. Tadalafil analogs.

Stefan O Ochiana1, Alden Gustafson, Nicholas D Bland, Cuihua Wang, Michael J Russo, Robert K Campbell, Michael P Pollastri.   

Abstract

In this Letter we describe our ongoing target repurposing efforts focused on discovery of inhibitors of the essential trypanosomal phosphodiesterase TbrPDEB1. This enzyme has been implicated in virulence of Trypanosoma brucei, the causative agent of human African trypanosomiasis (HAT). We outline the synthesis and biological evaluation of analogs of tadalafil, a human PDE5 inhibitor currently utilized for treatment of erectile dysfunction, and report that these analogs are weak inhibitors of TbrPDEB1.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22377518      PMCID: PMC3307956          DOI: 10.1016/j.bmcl.2012.01.118

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  12 in total

Review 1.  Drug resistance in Trypanosoma brucei spp., the causative agents of sleeping sickness in man and nagana in cattle.

Authors:  E Matovu; T Seebeck; J C Enyaru; R Kaminsky
Journal:  Microbes Infect       Date:  2001-07       Impact factor: 2.700

2.  Pharmacological validation of Trypanosoma brucei phosphodiesterases B1 and B2 as druggable targets for African sleeping sickness.

Authors:  Nicholas D Bland; Cuihua Wang; Craig Tallman; Alden E Gustafson; Zhouxi Wang; Trent D Ashton; Stefan O Ochiana; Gregory McAllister; Kristina Cotter; Anna P Fang; Lara Gechijian; Norman Garceau; Rajiv Gangurde; Ron Ortenberg; Mary Jo Ondrechen; Robert K Campbell; Michael P Pollastri
Journal:  J Med Chem       Date:  2011-11-08       Impact factor: 7.446

3.  Human African trypanosomiasis.

Authors:  Reto Brun; Johannes Blum; Francois Chappuis; Christian Burri
Journal:  Lancet       Date:  2009-10-14       Impact factor: 79.321

Review 4.  Therapeutic potential of phosphodiesterase inhibitors in parasitic diseases.

Authors:  Yasmin Shakur; Harry P de Koning; Hengming Ke; Junichi Kambayashi; Thomas Seebeck
Journal:  Handb Exp Pharmacol       Date:  2011

5.  Phosphodiesterase inhibitors as a new generation of antiprotozoan drugs: exploiting the benefit of enzymes that are highly conserved between host and parasite.

Authors:  Thomas Seebeck; Geert Jan Sterk; Hengming Ke
Journal:  Future Med Chem       Date:  2011-08       Impact factor: 3.808

6.  Drug to genome to drug: discovery of new antiplasmodial compounds.

Authors:  Terence B Beghyn; Julie Charton; Florence Leroux; Guillaume Laconde; Arnaud Bourin; Paul Cos; Louis Maes; Benoit Deprez
Journal:  J Med Chem       Date:  2011-04-19       Impact factor: 7.446

7.  The Trypanosoma brucei cAMP phosphodiesterases TbrPDEB1 and TbrPDEB2: flagellar enzymes that are essential for parasite virulence.

Authors:  Michael Oberholzer; Gabriela Marti; Mario Baresic; Stefan Kunz; Andrew Hemphill; Thomas Seebeck
Journal:  FASEB J       Date:  2006-12-13       Impact factor: 5.191

Review 8.  Cyclic nucleotide signaling mechanisms in trypanosomes: possible targets for therapeutic agents.

Authors:  Sunil Laxman; Joseph A Beavo
Journal:  Mol Interv       Date:  2007-08

9.  Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules.

Authors:  Byung-Je Sung; Kwang Yeon Hwang; Young Ho Jeon; J I Lee; Yong-Seok Heo; Jin Hwan Kim; Jinho Moon; Jung Min Yoon; Young-Lan Hyun; Eunmi Kim; Sung Jin Eum; Sam-Yong Park; Jie-Oh Lee; Tae Gyu Lee; Seonggu Ro; Joong Myung Cho
Journal:  Nature       Date:  2003-09-04       Impact factor: 49.962

10.  Crystal structure of the Leishmania major phosphodiesterase LmjPDEB1 and insight into the design of the parasite-selective inhibitors.

Authors:  Huanchen Wang; Zier Yan; Jie Geng; Stefan Kunz; Thomas Seebeck; Hengming Ke
Journal:  Mol Microbiol       Date:  2007-10-17       Impact factor: 3.501

View more
  9 in total

1.  Synthesis and evaluation of human phosphodiesterases (PDE) 5 inhibitor analogs as trypanosomal PDE inhibitors. Part 1. Sildenafil analogs.

Authors:  Cuihua Wang; Trent D Ashton; Alden Gustafson; Nicholas D Bland; Stefan O Ochiana; Robert K Campbell; Michael P Pollastri
Journal:  Bioorg Med Chem Lett       Date:  2012-02-09       Impact factor: 2.823

2.  Repurposing human PDE4 inhibitors for neglected tropical diseases: design, synthesis and evaluation of cilomilast analogues as Trypanosoma brucei PDEB1 inhibitors.

Authors:  Emanuele Amata; Nicholas D Bland; Charles T Hoyt; Luca Settimo; Robert K Campbell; Michael P Pollastri
Journal:  Bioorg Med Chem Lett       Date:  2014-07-30       Impact factor: 2.823

3.  Optimization of physicochemical properties for 4-anilinoquinazoline inhibitors of trypanosome proliferation.

Authors:  Jennifer L Woodring; Kelly A Bachovchin; Kimberly G Brady; Mitchell F Gallerstein; Jessey Erath; Scott Tanghe; Susan E Leed; Ana Rodriguez; Kojo Mensa-Wilmot; Richard J Sciotti; Michael P Pollastri
Journal:  Eur J Med Chem       Date:  2017-10-06       Impact factor: 6.514

4.  Synthesis and assessment of catechol diether compounds as inhibitors of trypanosomal phosphodiesterase B1 (TbrPDEB1).

Authors:  Jennifer L Woodring; Nicholas D Bland; Stefan O Ochiana; Robert K Campbell; Michael P Pollastri
Journal:  Bioorg Med Chem Lett       Date:  2013-08-21       Impact factor: 2.823

5.  Discovery of novel Trypanosoma brucei phosphodiesterase B1 inhibitors by virtual screening against the unliganded TbrPDEB1 crystal structure.

Authors:  Chimed Jansen; Huanchen Wang; Albert J Kooistra; Chris de Graaf; Kristina M Orrling; Hermann Tenor; Thomas Seebeck; David Bailey; Iwan J P de Esch; Hengming Ke; Rob Leurs
Journal:  J Med Chem       Date:  2013-03-01       Impact factor: 7.446

6.  Repurposing human PDE4 inhibitors for neglected tropical diseases. Evaluation of analogs of the human PDE4 inhibitor GSK-256066 as inhibitors of PDEB1 of Trypanosoma brucei.

Authors:  Stefan O Ochiana; Nicholas D Bland; Luca Settimo; Robert K Campbell; Michael P Pollastri
Journal:  Chem Biol Drug Des       Date:  2014-11-18       Impact factor: 2.817

7.  Phenotypic, chemical and functional characterization of cyclic nucleotide phosphodiesterase 4 (PDE4) as a potential anthelmintic drug target.

Authors:  Thavy Long; Liliana Rojo-Arreola; Da Shi; Nelly El-Sakkary; Kurt Jarnagin; Fernando Rock; Maliwan Meewan; Alberto A Rascón; Lin Lin; Katherine A Cunningham; George A Lemieux; Larissa Podust; Ruben Abagyan; Kaveh Ashrafi; James H McKerrow; Conor R Caffrey
Journal:  PLoS Negl Trop Dis       Date:  2017-07-13

8.  The single cyclic nucleotide-specific phosphodiesterase of the intestinal parasite Giardia lamblia represents a potential drug target.

Authors:  Stefan Kunz; Vreni Balmer; Geert Jan Sterk; Michael P Pollastri; Rob Leurs; Norbert Müller; Andrew Hemphill; Cornelia Spycher
Journal:  PLoS Negl Trop Dis       Date:  2017-09-15

Review 9.  The ever unfolding story of cAMP signaling in trypanosomatids: vive la difference!

Authors:  Daniel N A Tagoe; Titilola D Kalejaiye; Harry P de Koning
Journal:  Front Pharmacol       Date:  2015-09-07       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.